Abiomed provides temporary percutaneous mechanical circulatory support devices and offers a continuum of care to heart failure patients.
Read moreAnnual Revenue
$1B
Abiomed's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 6B. Over the last four quarters, Abiomed's revenue has grown by 8.3%. Specifically, in Q4 2021's revenue was $261.2M; in Q3 2021, it was $248.1M; in Q2 2021, it was $252.6M; in Q1 2021, Abiomed's revenue was $241.2M.